Federal (United States) · Statute compilation
Pub. L. 115-52 — FDA Reauthorization Act of 2017
70 sections
70 sections
- Pub. L. 115-52, tit. I, sec. 101 (as amended)SHORT TITLE; FINDING.
- Pub. L. 115-52, tit. I, sec. 102 (as amended)AUTHORITY TO ASSESS AND USE DRUG FEES.
- Pub. L. 115-52, tit. I, sec. 103 (as amended)REAUTHORIZATION; REPORTING REQUIREMENTS.
- Pub. L. 115-52, tit. I, sec. 104 (as amended)SUNSET DATES.
- Pub. L. 115-52, tit. I, sec. 105 (as amended)EFFECTIVE DATE.
- Pub. L. 115-52, tit. I, sec. 106 (as amended)SAVINGS CLAUSE.
- Pub. L. 115-52, tit. II, sec. 201 (as amended)SHORT TITLE; FINDING.
- Pub. L. 115-52, tit. II, sec. 202 (as amended)DEFINITIONS.
- Pub. L. 115-52, tit. II, sec. 203 (as amended)AUTHORITY TO ASSESS AND USE DEVICE FEES.
- Pub. L. 115-52, tit. II, sec. 204 (as amended)REAUTHORIZATION; REPORTING REQUIREMENTS.
- Pub. L. 115-52, tit. II, sec. 205 (as amended)CONFORMITY ASSESSMENT PILOT PROGRAM.
- Pub. L. 115-52, tit. II, sec. 206 (as amended)REAUTHORIZATION OF REVIEW.
- Pub. L. 115-52, tit. II, sec. 207 (as amended)ELECTRONIC FORMAT FOR SUBMISSIONS.
- Pub. L. 115-52, tit. II, sec. 208 (as amended)SAVINGS CLAUSE.
- Pub. L. 115-52, tit. II, sec. 209 (as amended)EFFECTIVE DATE.
- Pub. L. 115-52, tit. II, sec. 210 (as amended)SUNSET DATES.
- Pub. L. 115-52, tit. III, sec. 301 (as amended)SHORT TITLE; FINDING.
- Pub. L. 115-52, tit. III, sec. 302 (as amended)DEFINITIONS.
- Pub. L. 115-52, tit. III, sec. 303 (as amended)AUTHORITY TO ASSESS AND USE HUMAN GENERIC DRUG FEES.
- Pub. L. 115-52, tit. III, sec. 304 (as amended)REAUTHORIZATION; REPORTING REQUIREMENTS.
- Pub. L. 115-52, tit. III, sec. 305 (as amended)SUNSET DATES.
- Pub. L. 115-52, tit. III, sec. 306 (as amended)EFFECTIVE DATE.
- Pub. L. 115-52, tit. III, sec. 307 (as amended)SAVINGS CLAUSE.
- Pub. L. 115-52, tit. IV, sec. 401 (as amended)SHORT TITLE; FINDING.
- Pub. L. 115-52, tit. IV, sec. 402 (as amended)DEFINITIONS.
- Pub. L. 115-52, tit. IV, sec. 403 (as amended)AUTHORITY TO ASSESS AND USE BIOSIMILAR FEES.
- Pub. L. 115-52, tit. IV, sec. 404 (as amended)REAUTHORIZATION; REPORTING REQUIREMENTS.
- Pub. L. 115-52, tit. IV, sec. 405 (as amended)SUNSET DATES.
- Pub. L. 115-52, tit. IV, sec. 406 (as amended)EFFECTIVE DATE.
- Pub. L. 115-52, tit. IV, sec. 407 (as amended)SAVINGS CLAUSE.
- Pub. L. 115-52, tit. V, sec. 501 (as amended)BEST PHARMACEUTICALS FOR CHILDREN.
- Pub. L. 115-52, tit. V, sec. 502 (as amended)PEDIATRIC DEVICES.
- Pub. L. 115-52, tit. V, sec. 503 (as amended)EARLY MEETING ON PEDIATRIC STUDY PLAN.
- Pub. L. 115-52, tit. V, sec. 504 (as amended)DEVELOPMENT OF DRUGS AND BIOLOGICAL PRODUCTS FOR PEDIATRIC CANCERS.
- Pub. L. 115-52, tit. V, sec. 505 (as amended)ADDITIONAL PROVISIONS ON DEVELOPMENT OF DRUGS AND BIOLOGICAL PRODUCTS FOR PEDIATRIC USE.
- Pub. L. 115-52, tit. VI, sec. 601 (as amended)REAUTHORIZATION OF PROVISION RELATING TO EXCLUSIVITY OF CERTAIN DRUGS CONTAINING SINGLE ENANTIOMERS.
- Pub. L. 115-52, tit. VI, sec. 602 (as amended)REAUTHORIZATION OF THE CRITICAL PATH PUBLIC-PRIVATE PARTNERSHIPS.
- Pub. L. 115-52, tit. VI, sec. 603 (as amended)REAUTHORIZATION OF ORPHAN GRANTS PROGRAM.
- Pub. L. 115-52, tit. VI, sec. 604 (as amended)PROTECTING AND STRENGTHENING THE DRUG SUPPLY CHAIN.
- Pub. L. 115-52, tit. VI, sec. 605 (as amended)PATIENT EXPERIENCE DATA.
- Pub. L. 115-52, tit. VI, sec. 606 (as amended)COMMUNICATION PLANS.
- Pub. L. 115-52, tit. VI, sec. 607 (as amended)ORPHAN DRUGS.
- Pub. L. 115-52, tit. VI, sec. 608 (as amended)PEDIATRIC INFORMATION ADDED TO LABELING.
- Pub. L. 115-52, tit. VI, sec. 609 (as amended)SENSE OF CONGRESS ON LOWERING THE COST OF PRESCRIPTION DRUGS.
- Pub. L. 115-52, tit. VI, sec. 610 (as amended)EXPANDED ACCESS.
- Pub. L. 115-52, tit. VI, sec. 611 (as amended)TROPICAL DISEASE PRODUCT APPLICATION.
- Pub. L. 115-52, tit. VII, sec. 701 (as amended)RISK-BASED INSPECTIONS FOR DEVICES.
- Pub. L. 115-52, tit. VII, sec. 702 (as amended)IMPROVEMENTS TO INSPECTIONS PROCESS FOR DEVICE ESTABLISHMENTS.
- Pub. L. 115-52, tit. VII, sec. 703 (as amended)REAUTHORIZATION OF INSPECTION PROGRAM.
- Pub. L. 115-52, tit. VII, sec. 704 (as amended)CERTIFICATES TO FOREIGN GOVERNMENTS FOR DEVICES.
- Pub. L. 115-52, tit. VII, sec. 705 (as amended)FACILITATING INTERNATIONAL HARMONIZATION.
- Pub. L. 115-52, tit. VII, sec. 706 (as amended)FOSTERING INNOVATION IN MEDICAL IMAGING.
- Pub. L. 115-52, tit. VII, sec. 707 (as amended)RISK-BASED CLASSIFICATION OF ACCESSORIES.
- Pub. L. 115-52, tit. VII, sec. 708 (as amended)DEVICE PILOT PROJECTS.
- Pub. L. 115-52, tit. VII, sec. 709 (as amended)REGULATION OF OVER-THE-COUNTER HEARING AIDS.
- Pub. L. 115-52, tit. VII, sec. 710 (as amended)REPORT ON SERVICING OF DEVICES.
- Pub. L. 115-52, tit. VIII, sec. 801 (as amended)PRIORITY REVIEW OF GENERIC DRUGS.
- Pub. L. 115-52, tit. VIII, sec. 802 (as amended)ENHANCING REGULATORY TRANSPARENCY TO ENHANCE GENERIC COMPETITION.
- Pub. L. 115-52, tit. VIII, sec. 803 (as amended)COMPETITIVE GENERIC THERAPIES.
- Pub. L. 115-52, tit. VIII, sec. 804 (as amended)ACCURATE INFORMATION ABOUT DRUGS WITH LIMITED COMPETITION.
- Pub. L. 115-52, tit. VIII, sec. 805 (as amended)SUITABILITY PETITIONS.
- Pub. L. 115-52, tit. VIII, sec. 806 (as amended)INSPECTIONS.
- Pub. L. 115-52, tit. VIII, sec. 807 (as amended)REPORTING ON PENDING GENERIC DRUG APPLICATIONS AND PRIORITY REVIEW APPLICATIONS.
- Pub. L. 115-52, tit. VIII, sec. 808 (as amended)INCENTIVIZING COMPETITIVE GENERIC DRUG DEVELOPMENT.
- Pub. L. 115-52, tit. VIII, sec. 809 (as amended)GAO STUDY OF ISSUES REGARDING FIRST CYCLE APPROVALS OF GENERIC MEDICINES.
- Pub. L. 115-52, tit. IX, sec. 901 (as amended)TECHNICAL CORRECTIONS.
- Pub. L. 115-52, tit. IX, sec. 902 (as amended)ANNUAL REPORT ON INSPECTIONS.
- Pub. L. 115-52, tit. IX, sec. 903 (as amended)STREAMLINING AND IMPROVING CONSISTENCY IN PERFORMANCE REPORTING.
- Pub. L. 115-52, tit. IX, sec. 904 (as amended)ANALYSIS OF USE OF FUNDS.
- Pub. L. 115-52, tit. IX, sec. 905 (as amended)FACILITIES MANAGEMENT.